The compound was well-tolerated, with negligible incidences of nausea and vomiting across all arms of the study. Trends towards weight loss were also observed. “It is remarkable to
The patent details methods used to develop sofosbuvir-based medicines for the treatment of patients with hepatitis C virus (HCV) infection, including Sovaldi and Harvoni. The jury’s verdict upholds patent
VistaGen licensed exclusive rights of the cardiac stem cell technologies from University Health Network (UHN), Canada's largest research hospital, pursuant to a strategic research agreement with UHN and
Goldfinch was launched with $55m in Series A financing to translate breakthroughs in genetics and kidney biology to lead a new era of therapeutic development targeting the molecular
Ocaliva is a potent and selective agonist of the farnesoid X receptor (FXR), which is expressed at high levels in the liver and intestine and thought to be
REKOVELLE is the first rFSH to be derived from a human cell line and is the first rFSH treatment to be administered with an individualised dosing regimen. REKOVELLE’s
Proton Partners will invest £30m in its cancer centre which will be located at the Thames Valley Science Park and will offer proton beam therapy among other conventional
Up to 200 new jobs will be created at the Rockville facility, with GSK investing over $50m in the next two years to continue to develop the site
Qutenza is approved by the European Medicines Agency (EMA) for the treatment of peripheral neuropathic pain (PNP). Grünenthal will hold exclusive rights for Qutenza in all 28 European
When used along with diet and exercise, SYNJARDY XR is indicated to improve blood sugar in adults with type 2 diabetes when both empagliflozin and metformin can be
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.